Zymeworks Inc.
0 products tracked · names used in filings: Zymeworks Inc.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Ziihera: PDUFA target action date (first-line HER2-positive unresectable locally advanced or metastatic gastric, GEJ, or gastroesophageal adenocarcinoma (G)
Zymeworks Inc. (ZYME); zanidatamab-hrii; sBLA; status: set; "FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026 • China’s NMPA has accepted the sBLA for zanidatamab;…"; filed 2026-05-07 · source
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.